



Universiteit
Leiden
The Netherlands

Effect of glucose regulation on renal parenchyma and sinus fat volume in patients with type 2 diabetes

Lin, L.; Dekkers, I.A.; Tao, Q.; Paiman, E.H.M.; Bizino, M.B.; Jazet, I.M.; Lamb, H.J.

Citation

Lin, L., Dekkers, I. A., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2023). Effect of glucose regulation on renal parenchyma and sinus fat volume in patients with type 2 diabetes, *49*(1). doi:10.1016/j.diabet.2022.101408

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3563145>

Note: To cite this publication please use the final published version (if applicable).



Available online at
ScienceDirect
 www.sciencedirect.com

Elsevier Masson France
EM|consulte
 www.em-consulte.com



Research letter

Effect of glucose regulation on renal parenchyma and sinus fat volume in patients with type 2 diabetes



To the editor

Kidney enlargement and sinus fat accumulation have been found in patients with type 2 diabetes mellitus (T2DM) and are associated with increased risk of diabetic kidney disease (DKD) [1, 2]. Strict glycemic control has been shown to delay and slow the progression of DKD [3]. However, it remains uncertain whether renal parenchyma volume and sinus fat volume decrease after glucose-lowering treatment.

Previously, we found larger renal parenchyma volume and greater sinus fat volume in patients with T2DM than in healthy controls based on magnetic resonance imaging (MRI) [4]. We also found that sinus fat volume was positively associated with glycated hemoglobin (HbA1c) and urinary albumin-to-creatinine ratio (UACR), making it a potential imaging biomarker for DKD at an early phase [5]. We present here the follow-up study aiming to assess whether renal parenchyma volume and sinus fat volume decrease after 26 weeks of intensive glucose-lowering therapy in patients with T2DM, and whether liraglutide, a glucagon-like peptide-1 (GLP-1) receptor analogue, has added effect on renal volumes in addition to standard treatment.

This study is an assessor-blinded secondary analysis of the randomized, double-blind, single-center clinical trial MAGNA VICTORIA studies (ClinicalTrials.gov NCT01761318 [5], NCT02660047 [6]), in which 93 patients with T2DM were randomized to receive liraglutide ($n = 43$) or placebo ($n = 50$) for 26 weeks in addition to metformin, sulfonylurea derivative and/or insulin. At baseline and 26 weeks after treatment, participants had medical history assessment, physical examination, blood examination and MRI scans. Renal parenchyma volume and sinus fat volume were measured on the high-resolution water-fat separated images (Fig. 1) obtained by a 3.0 Tesla MRI scanner (Ingenia, Philips Medical Systems, Best, the Netherlands). Detailed information of the MRI protocol and clinical data collection has been reported in our previous publications [4–6]. All statistical analyses were performed with SPSS v.25 (IBM, Armonk, NY). Within-group differences were assessed using paired t-tests. Between-group differences were analyzed using analysis of covariance (ANCOVA) with adjustment for the baseline values, and the effect size was reported as means (95%CI). Linear regression models were constructed to analyze the associations between renal volumes and clinical characteristics.

After 26-week glucose-lowering treatment, renal parenchyma volume decreased with statistical significance, while renal sinus volume did not change in the whole cohort (Table 1). The level of fasting glucose and HbA1c significantly decreased in the whole cohort. Significant decreases in weight, waist circumference, triglycerides, total cholesterol, low density lipoprotein, abdominal visceral adipose tissue (VAT) and subcutaneous adipose tissue were also

observed. The decrease in parenchyma volume was positively associated with the decreases in fasting glucose, HbA1c and abdominal VAT, which persisted after adjustment for age, sex, treatment allocation and ethnicity.

Subgroup analysis showed that the decrease of parenchyma volume was statistically significant in the liraglutide group and larger than that in the placebo group. However, no additional effects of liraglutide as compared to placebo on parenchyma volume was observed after adjustment for baseline volume. Nor was the effect on sinus fat volume.

Kidney enlargement can be found from the onset of diabetes due to expanded nephron size, particularly hypertrophy of the proximal tubule [7]. Both obesity and hyperglycemia can induce glomerular hyperfiltration through various cytokines and growth factors, which leads to nephromegaly. On the other hand, nephromegaly increases filtration surface area per glomerulus and exacerbates hyperfiltration. Our findings indicate that the decrease of renal parenchyma volume in response to the glucose-lowering treatment in T2DM might reflect the comprehensive benefits associated with lowered glucose level and reduced abdominal VAT. The improved glucose control and the loss of VAT may reduce the secretion of neurohormonal stimuli and ameliorate glomerular hyperfiltration, thus lead to the decrease of renal parenchyma volume.

Our baseline analysis demonstrated larger sinus fat volume in patients than in healthy controls, and baseline sinus fat volume was associated with HbA1c, VAT and blood lipids [4]. After treatment, however, sinus fat volume remained unchanged despite the significant decrease of HbA1c, VAT, triglyceride and cholesterol. These results suggest that the metabolism of renal sinus fat and the general abdominal VAT might not be synchronous, which adds further evidence for the morphological and functional heterogeneity among different anatomical patterns of fat accumulation.

In conclusion, renal parenchyma enlargement in T2DM can be potentially reversed by glucose-lowering treatment. Our findings suggested that renal parenchyma volume is a promising biomarker to monitor the hyperfiltration and hypertrophy of the kidneys in the development of DKD. On the other hand, renal sinus fat in patients with T2DM might be regulated by unique pathophysiological pathways that are independent from the metabolism of abdominal VAT and blood lipids. However, these results need to be validated in larger populations with longer follow-up periods in the future.

Funding

This investigator-initiated study was funded by Novo Nordisk (Denmark). Novo Nordisk had no role in the design of the study, data collection, data analysis, data interpretation, or writing of the




Fig. 1. The measurements of renal parenchyma volume (red) and sinus fat volume (yellow). Renal parenchyma was labelled on transversal fat-only images (a), and renal sinus fat was defined by a straight line (white line) tangent to the margins of parenchyma. Renal pelvis, calyces and vasculatures were manually discarded based on the water-only images (b). Renal parenchyma and sinus fat volume were calculated by summing the labelled voxels (c).

Table 1
Effects of glucose regulation on renal volumes and clinical characteristics.

	Baseline	Follow-up	Δ (follow-up – baseline)	P value*
Renal volumes				
Parenchyma volume (cm ³)	170.4 ± 39.0	168.3 ± 39.1	-2.1 ± 7.6	0.009
Sinus fat volume (cm ³)	15.3 ± 7.5	15.2 ± 7.9	-0.1 ± 2.2	0.748
Clinical characteristics				
Weight (kg)	88.1 ± 15.1	86.1 ± 15.4	-2.0 ± 3.5	< 0.001
Waist circumference (cm)	105.5 ± 10.3	104.9 ± 11.3	-0.6 ± 4.3	0.196
Triglycerides (mmol/L)	1.7 (1.1, 2.6)	1.3 (1.0, 2.1)	-0.3 ± 1.2	0.014
Total cholesterol (mmol/L)	4.5 ± 1.0	4.2 ± 1.0	-0.3 ± 0.9	< 0.001
HDL (mmol/L)	1.2 ± 0.3	1.2 ± 0.3	-0.01 ± 0.17	0.564
LDL (mmol/L)	2.3 ± 0.9	2.2 ± 0.8	-0.2 ± 0.7	0.019
Abdominal VAT (cm ²)	184.3 ± 67.0	177.7 ± 66.2	-6.6 ± 27.1	0.021
Abdominal SAT (cm ²)	334.5 ± 124.2	321.0 ± 123.7	-13.5 ± 37.3	0.001
Fasting Glucose (mmol/L)	8.1 ± 2.7	7.1 ± 2.6	-1.0 ± 2.4	< 0.001
HbA _{1c} (mmol/mol)	66.6 ± 11.2	58.2 ± 11.2	-8.5 ± 10.2	< 0.001
Creatinine (μmol/L)	70.0 ± 18.5	72.2 ± 18.5	2.3 ± 7.4	0.004
eGFR (mL/min per 1.73 m ²)	93.7 ± 14.9	91.5 ± 15.6	-2.1 ± 7.0	0.004
Square root of UACR	2.0 ± 3.1	1.7 ± 2.1	-0.3 ± 2.0	0.100

VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; UACR, urinary albumin-to-creatinine ratio.

* P value calculated by paired *t*-test.

report. Dr. Ling Lin was funded by China Scholarship Council (CSC201807720065).

Declaration of Competing Interest

The authors declare no conflicts of interest.

Acknowledgements

We express our gratitude to all individuals who participated in the MAGNA VICTORIA. We are grateful for all participating general practitioners and nurses, and the physicians and nurses of the Haaglanden Medical Center (The Hague, The Netherlands) for inviting eligible participants.

References

- [1] Baumgartl H-J, Sigl G, Banholzer P, Haslbeck M, Standl E. On the prognosis of IDDM patients with large kidneys. *Nephrology, Dialysis, Transplantation* 1998;13(3):630–4.
- [2] Notohamiprodjo M, Goepfert M, Will S, Lorbeer R, Schick F, Rathmann W, et al. Renal and renal sinus fat volumes as quantified by magnetic resonance imaging in subjects with prediabetes, diabetes, and normal glucose tolerance. *PLoS ONE* 2020;15(2):e0216635.
- [3] Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321(7258):405–12.
- [4] Lin L, Dekkers IA, Huang L, Tao Q, Paiman EHM, Bizino MB, et al. Renal sinus fat volume in type 2 diabetes mellitus is associated with glycated hemoglobin and metabolic risk factors. *J Diabetes Complicat* 2021:107973.
- [5] Bizino MB, Jazet IM, Westenberg JJ, van Eyk HJ, Paiman EH, Smit JW, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. *Cardiovasc Diabetol* 2019;18(1):55.

- [6] van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, et al. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. *Cardiovasc Diabetol* 2019;18(1):87.
- [7] Vallon V, Komers R. Pathophysiology of the diabetic kidney. *Compr Physiol* 2011;1(3):1175–232.

Ingrid M. Jazet
Eindhoven Laboratory for Experimental Vascular Medicine, Leiden
University Medical Center, Albinusdreef 2, Leiden 2333ZA, The
Netherlands

Ling Lin*
Department of Radiology, The Eighth Affiliated Hospital, Sun Yat-sen
University, Shennan Middle Road 3025, Shenzhen, Guangdong, China
Department of Radiology, Leiden University Medical Center, Albinusdreef
2, Leiden 2333ZA, The Netherlands

Hildo J. Lamb
Department of Radiology, Leiden University Medical Center, Albinusdreef
2, Leiden 2333ZA, The Netherlands

Ilona A. Dekkers
Qian Tao
Elisabeth H.M. Paiman
Maurice B. Bizino
Department of Radiology, Leiden University Medical Center, Albinusdreef
2, Leiden 2333ZA, The Netherlands

*Corresponding author.
E-mail address: linling26@mail.sysu.edu.cn (L. Lin).

Received 7 November 2022
Accepted 12 November 2022

Available online 15 November 2022